Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The boron atom in bortezomib binds the catalytic site of the 26S proteasome with high affinity and specificity. In May 2003, bortezomib became the first anticancerproteasome inhibitor that was approved by the FDA.
SynZeal offers all Bortezomib related impuritiesstandards with certified COA and characterization data like IR, Mass, HPLC, purity, NMR & TGA report. We also provide CMR, DEPT and detailed structure characterization report as per requirements. Bortezomib related standards are being used by major pharmaceuticalcompanies across the globe for their ANDA/DMF filing.
.png)
